Drug Profile
Research programme: HIV-1 infection therapeutics - Cocrystal Pharma
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator RFS Pharma LLC
- Developer Cocrystal Pharma Inc; Emory University; University of Pittsburgh
- Class
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in USA
- 25 Nov 2014 RFS Pharma has merged with Cocrystal Pharma Inc to form Advanced Antiviral Development Organization
- 11 Feb 2009 Antimicrobial data from a preclinical trial in HIV-1 infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)